SAN FRANCISCO, CALIFORNIA, Feb. 17, 2026 (GLOBE NEWSWIRE) — GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary TriKE® natural killer (NK) cell engager platform, today announced that Michael Breen, Executive Chairman and Chief Executive Officer of GT Biopharma, will be participating in the Centurion One Capital 9th Annual Toronto Growth Conference on Thursday, March 5th, 2026, in Toronto, Ontario.
This excerpt is quoted from the original release. Read the full announcement on GlobeNewsWire.
Brief Summary
GT Biopharma, Inc. is poised to present at the upcoming Centurion One Capital 9th Annual Toronto Growth Conference, highlighting its innovative progress in immuno-oncology.
- CEO Michael Breen will share insights on the company’s proprietary TriKE® technology.
- Conference date: March 5th, 2026, in Toronto, Ontario.
- Focus: Development of cancer therapeutics using natural killer (NK) cells.
- Investors can gain valuable industry insights during this event.
Why it matters: This conference offers a platform for GT Biopharma to connect with investors and showcase its advancements in the field of oncology.
Read the Full Article
This is a summary of the press release. For the complete article and any additional details, please visit the original source.
Attribution: Original press release by GlobeNewsWire on . We provide an AI-generated summary and links for convenience. Always verify details with the original source. Not investment advice. For informational purposes only.
